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Abstract This article describes predictive, preventive value of
genetic tests and the implication of the use of testing for
personalized treatment. This year marks the 10th anniversity of
publishing of the sequence of the human genome. One
important area of application of this mega project is a
development of genetic tests for mutation detection in single
gene disorders that has impact for pediatric age group patients
and analyzing susceptibility genes as risk factors in common
disorders. Types of genetic tests, new emerging technologies
will enable developments of high-throughput approaches by
microarrays of great application capacity as described here. As
it is usual for all technologies used in health care, bioethical
concerns has to be delt with. The ethical, social and governance
issues associated with genetic testing are discussed.
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The Human Genome Project (HGP), which was initiated in
the 1990s, is usually labeled as the mega project of 20th
century that has revolutionized biomedical sciences [1].
With the sequencing of the human genome completed in
the last decade medical science is looking forward to
advances in the diagnosis, prevention and treatment of
Mendelian as well as common disorders. Consequently, we
are moving to the area characterized as personalized
medicine in health care [2–4]. It is also expected that genomics
will play a major role in new drug design for disease related
pathways and also be used as a predictive tool for individual
responses to drugs [5]. The research dedicated to genetics/
genomics is expected to have a high impact on pediatric
practice where one area of application relevant to information
gained from the HGP is genetic testing of germline DNA
variations or acquired changes in the somatic tissues such as
cancer [6]. There are over 5000 inherited monogenic diseases
affecting children and prevelance at birth of this diseases is
around 10/1000 [7]. These rare diseases are very severe and
usually can not be cured. Therefore, genetic testing in
diagnosis of monogenic disorders is a relevant area of
research and health care practice in pediatric age group of
patients [8].
There are different types of genetic testing defined as [9,
10]:
Newborn screening is used immediately following
birth to identify treatable conditions to ensure that
treatment begins as early as possible before irreversible
damage takes hold [11]. One of the diseases first
introduced in the newborn screening programs was
phenylketonuria (PKU), the first example of a treatable
genetic condition. Today, there are more than 30
diseases that are included in the screening programs.
The following criteria proposed by James M.G. Wilson
and Gunnar Jungner [12] as given below, are widely used to
assess the validity of screening for a given condition:
“The condition being screened for should be an
important health problem;
The natural history of the condition should be well
understood;
There should be a detectable early stage;
Treatment at an early stage should be of more benefit
than at a later stage;
A suitable test should be devised for the early stage;
The test should be acceptable;
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Intervals for repeating the test should be determined;
Adequate health service provision should be made for
the extra clinical workload resulting from screening;
The risks, both physical and psychological, should be
less than the benefits.”
Diagnostic testing is done to confirm or rule out a
diagnosis made by physical examination. It can be
done at the post-natal or pre-natal stage during
pregnancy. There are more than 2,000 clinical and
research tests available today (www.ncbi.nlm.nih.gov/
sites/GeneTests).
In prenatal testing, fetal cells can be obtained by invasive
procedures such as amniocentesis at the 13th-15th of
pregnancy by the aspiration of amniotic fluid sample [13].
Another invasive procedure is chorionic vilus sampling
where chorionic tissue of fetal trophoblast origin can be
obtained at the 12th week of gestation [14].
For genetic testing new non-invasive procedures are
coming into use. Fetal cells from maternal circulation and
cell free fetal nucleic acid (cffNA) from pregnant women are
beginning to be used for diagnosis [15]. Analysis of fetal
aneupleudies is a recent application of the use of cffNA [16].
Prenatal diagnosis can allow for prevention or very early
intervention for management of monogenic diseases.
Pre-implantation testing is a form of prenatal testing
where embryos created through in vitro fertilization are
tested for a particular disease, and only the healthy
embryos are implanted in the uterus for the pregnancy
[17].
Carrier screening is done to test if any person with a
positive family history carries a mutant copy of the
gene. In some ethnic groups where a particular gene
mutation is high, couples can request premarital testing
to obtain information about the risk of their having a
child with the disease. One well known population
screening program was established for the Ashkenazi
Jewish population where the frequency of Tay-Sachs
Disease (GM2 Gangliosidosis type B) is quite high (1/
3600) [18].
Predictive testing can be done in cases with positive
family history to test for mutations that cause disease
only later in life, such as Huntington’s disease. Since
there are no signs of disease at the time of testing, this
type of testing can also be called presymptomatic
testing. With increased information available to med-
ical practitioners, it is expected that predictive testing
will have a broad applications for common disorders
such as diabetes, hypertension, coronary heart disease
and Alzheimer’s, where genetic variations that cause
susceptibility to a particular disease and, thus, become
a risk factor can be detected very early in life. This
type of testing holds the promise of prevention through
life style improvements or personalized medication,
where each genotype will direct the course of specific
therapy. However, pediatric applications of predictive
testing is rife with ethical issues and controversies that
need to be addressed properly, so that testing results
can be used for the patient benefits, rather than
harming the patients [19].
Pharmacogenetic testing is used to assess responsive-
ness to drug therapy. Taking into account individual
factors as contributing elements to the outcome of
therapy, before assigning the use of a drug, paves the
way to “personalized medication.” So far, this type of
testing has found applications mostly in cancer drugs.
There is still a long way for methodologies to become
available in a hospital setting, so that personal drug
prescriptions according to genotypic findings can have
a real positive impact on clinical practices [20, 21].
Modifications on the predicted effects of genetic
variations
The basic outcome of a genetic test is the physician’s ability
to predict the phenotype of the patient and take preventive
measures or design the management of the disease.
Hopefully, by further advances and appliactions of geno-
typic predictions personalized therapies based on the
individual genome information will come into practice.
However, investigations into the molecular pathophysi-
ology of Mendelian diseases have revealed various mech-
anisms that make it difficult to prediction the phenotypic
outcome [22].
Genetic heterogeneity and genetic modifiers can play a
role, so that a determination of the predictive variation on
the single gene level may not reflect the phenotype directly.
These mechanisms need to be taken into consideration
during the interpretation of test results as well as the
counseling of patients and their families.
Deafness is a well known example with high degree of
heterogeneity. With over one hundred genes identified, a
testing is overwhelming. The variability of the phenotype,
further, contributes to the complexity of the prediction of
the outcome based on an individual’s test results [23].
Another cause of variability is the presence of
modifying affects to the phenotype. Cystic Fibrosis
(CF) is an example of an AR monogenic disease where
modifiers have been identified. The severity of the lung
disease in CF has been shown to be affected bymodifier genes
and environmental factors. Polymorphisms identified in genes
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for transforming growth factor β1, Mannose binding lectin 2,
tumor necrosis factor α and mutations in alpha1 antitrypsin
gene, all lead to a variability in the lung function of CF
patients [24, 25]. The further source of variability are
nucleotide repeats in intronic regions of the CF transmem-
brane conductance regulator (CFTR) gene [26].
Another example can be given for more than 20
neuromuscular and neurodegenerative diseases, where a
disease phenotype is due to expanded poly-amino acid
tracts. These trinucleotide repeats can take place in coding
or noncoding regions of genes involved in diseases such as
Huntington’s disease, myotonic dystrophy, fragile X mental
retardation syndrome (FMR1). The repeats become unsta-
ble, if expansion increases through transmission to next
generations with the concomitant increase of severity of the
phenotype, the phenomenon called anticipation [27, 28].
That makes it difficult to predict the outcome of disease
solely according to the detected DNA variation.
Predictive value of genetic testing for personalized
therapy
Individualized drug therapy based on findings of DNA
variations in pediatrics is exemplified in monogenic
diseases such as CF and Duchenne Muscular Dystrophy
(DMD), and also in childhood cancers such as Acute
Lenfoblastic Leukemia (ALL).
In CF, mutations in the CFTR gene cause abnormal salt
and water transport across epithelial surfaces in systems
such as the hepato-bilary gastrointestinal, respiratory and
reproductive systems, as well as in the sweat glands. The
identification of the CFTR gene confirmed the findings that
chloride secretion was defective in CF [29].
Therapies for CF have so far aimed at alleviating the end
organ damage in different systems, such as pancreatic
enzyme replacement, and in therapies for lung disease, such
as mucus retention, inflammation and infection. However,
none of these therapies can correct the underlying molec-
ular defects of the mutant CFTR gene. Compounds that are
classified as potentiators and correctors are being investi-
gated as gene targeting chemicals. Potentiators play a role
in allowing the CFTR channel to stay open longer, thus
allowing more chloride ions to pass through and are
candidates for corrections of Class I mutations such as
G551D and delta F508 [30]. VX-770 is a potentiator
(Vertex Pharmaceuticals) that is being used in Phase III
clinical trials for patients with at least one allele carrying
the G551D mutation, and also in Phase II trials in
homozygous patients for delta F508 mutation (www.
clinicaltrials.gov).
As for correctors, these are compounds that facilitate the
movement of delta F508 CFTR from the ER to the apical
membranes. Quinazoline VRT-325, aminoarylthiazoles and
bisaminomethylbithiazoles are therapeutics under investi-
gation [31].
Table 1: In CF therapies [31, www.cff.org, www.
clinicaltrials.gov] are directed to the consequences of the
non-functional CFTR which are related to abnormal ion
transport. New therapies are emerging where the novel
compounds are targeted specifically against the defect of
the gene variant which holds promise for personalized
medicine.
Another example of potential therapeutic compounds,
that are being investigated, are chemicals that aim at stop
codon mutations, where a premature stop in translation
results in a truncated protein product with loss of function
[32]. In DMD, Ataluren (PTC124-3-[5-(2-fluorophenyl)-
1,2,4-oxadiazol-3-yl]benzoic acid) is an experimental drug
that has been shown to suppress the premature termination
and restoration of dystrophin protein production in vitro
and in mdx mice [33].
In cancer patients, pharmacogenetic testing can identify
those who may run the risk of developing toxicity to
chemotherapeutic agents, thus allowing for an individual-
ized regiment for therapy [34]. For example, decreased
enzyme activity has been determined for variant forms of
the enzyme thiopurine methyl transferase (TPMT). G238C,
G460A, and A719G are the prevalent mutations in
Caucasians, and A719G is the prevalent variant in Asian,
African and African-American populations that lead to 80–
Table 1 Therapies for cystic fibrosis
Treatment of Clinical Consequences
1. Pancreatic Disease • Pancreatic enzyme replacement (PERT)
2. Lung Disease
a) Mucus clearance • DNAse - Pulmozyme (Genentech)
• UTP analog - Donufosol
(Inspire Pharmaceuticals)
• Lantibiotic - Duramycin
(Moli 1901 - Lantibio)
• Hypertonic saline
b) Anti-inflammation • Nonsteroidal anti-inflammatory
drugs - Ibuprofen
• Corticosteroids - Prednisone
• Macrolide antibiotics - Zithromax
c) Anti-microbial • TOBI (Novartis) - for P.aeruginosa
Gene Variant Targeted Pharmaceutical Compounds
(Personalized Treatment)
Protein truncation • Aminoglycoside antibiotics - Gentamicin
• Non-aminoglycoside compounds -
PTC124 (Ataluren) (PTC Therapeutics)
Channel regulation • Vx-770 (Vertex pharmaceuticals) -




• Vx-809 (Vertex pharmaceuticals) -
ΔF508 Mutation
95% decreased activity resulting in thiopurine drug toxicity
in childhood ALL treatment with 6-mercaptopurine, 6-
thioguanine and azathiopurine. Testing prior to therapy will




Molecular genetic testing owes its analytical validity much to
the use of Polymerase Chain Reaction (PCR) where a segment
of DNA can be amplified in vitro, and the presence of a
disease causing mutation can be checked by various methods,
such as Restriction Fragment Length Polymorphism (RFLP)
utilizing restriction enzymes or sequencing technology to
identify novel mutations within the amplified segments [36].
Although these methods are now within standard operation
procedures for mutation detection at many genetic testing
labs, the capacity is limited for testing of a very few samples
simultaneously.
Arrays may be described as chips depicted as in Fig. 1,
carrying multiples of assays that allow for testing of tens of
thousands of different variants simultaneously, and they are
beginning to find wide clinical use [37]. Single nucleotide
polymorphism (SNP) genotyping arrays and resequencing
are two high throughput examples used to identify genetic
variants. HGP has led to the discovery of many SNPs as a
source of genetic variation, and genotyping for SNPs has
played a major role in international efforts to map for
disease susceptibility genes [38].
In some monogenic diseases, multigenic inheritance and
genetic heterogeneity make diagnosis quite taxing. In such
cases, SNP microarray applications for homozygosity
mapping to identify disease locus in children from
consanguineous parents facilitates the diagnosis [39].
Microarrays are further employed in studies, such as
those analyzing cancer tissues, to identify acquired
somatic mutations or gene expresson patterns that have
prognostic and therapeutic value in childhood cancers
[40–42].
Array technologies can also increase the capacity of
newborn screening programs. Guthrie cards, which are used
to store blood spots from newborns are a valuable source of
genetic material. However, the yield of extracted DNA is
usually very low. With improved methods developed to
obtain higher yields of DNA of better quality, genome scale
microarray analysis is becoming commercially available
[43]. This will increase the capacity of newborn screening
programs to detect multitudes of variations that may have
predictive implications for the neonate. As seen from the
examples above, microarrays have a wide range of applica-
tions. Technical advances are increasingly enabling the
marketing of higher density arrays with decreasing costs,
resulting in the wider use of microarrays for research and
clinical purposes, thus, aiding the identification of new
disease genes, diagnosis of disease causing mutations and
susceptibility variants with predictive value [44].
Copy Number Variation (CNV) detection: CNV can be
described as a segment of DNA that carries a different copy
number as compared to a reference genome sequence.
Submicroscopic alterations such as insertions/duplications
or deletions constitute the structural genetic variation that
can be detected by tecniques such as comparative genome
hybridization (CGH) or chromosomal microarray (CMA)
[45].
CNVs are beginning to be found as associated with
diseases such as asthma, autoimmune diseases, autism and
schizophrenia. Genetic experts recommend CMA for
Fig. 1 Basic steps of microarray
analysis: The synthetic oligonu-
cleotides are either plotted or
directly synthesized on a solid
surface that can be described as a
“chip” (1). Fluorescent labelled
DNA samples can be used for
techniques such as SNP analysis,
re-sequencing applications or
cDNA samples utilized in tran-
scriptomics for gene expression
analysis (2). Sequence comple-
mentarity between the probe and
the sample target allows for hy-
bridization (3). Bioinformatics
tools are used to process the
generated signals followed by hy-
bridization and washing steps (4)
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screening children with congenital abnormalities, autism
spectrum disorders and developmental delays [46, 47].
Whole genome sequencing (WGS) The identification of any
sequence of DNA with a disease causing variation has the
potential for accurate diagnosis and proper therapy. The
automated Sanger method is the classical sequencing
technology currently used worldwide to identify genomic
variations. However, this technology is not effective in
sequencing an entire genome within a reasonable amount of
time at a reasonable cost. Technology is taking long strides
towards ‘next generation sequencing’ technologies where
an entire genome can be sequenced in a short period of time
with high resolution and efficiency [48, 49]. The realization
of the ultimate vision of “personalized medicine” depends
on the future use of WGS for genotyping of individual
genomes. Although the cost is prohibitive today and WGS
is used only in research settings, it is hoped that falling
costs (ultimately assumed as 1,000 USD/Genome) will
enable genetic testing laboratories to employ WGS in
clinical settings [50].
Genome Wide Association Studies (GWAS) GWAS is a
powerful tool for prediction of risk in common diseases.
When compared to monogenic diseases where only
mutations in one single gene are the causative factor, in
complex diseases multiple genes interact with the environ-
ment to lead to the phenotype. Since they are more
prevalent in the populations, it is obvious that trying to
predict the genetic risk factors from an early age and
developing appropriate genetic tests for these multifactorial
diseases will be an important advance in health care.
Prevention of disease and personalized treatment modalities
based on the genetic make up of individuals is a priority
area of biomedical research. Towards this goal, new high
resolution technologies are being developed. GWAS relies
on the new microarray technologies to study simulta-
neously the associative role of thousands of SNPs as
genetic risk factors for common traits. So far, these studies
are in preclinical phase to use GWAS results in health care
and management of disease, that needs to definite
association of one single variant as the susceptibility
factor for the disease phenotype. GWAS for complex
diseases such as bipolar disorder, coronary artery disease,
Crohn’s disease, hypertension, rheumatoid arthritis, type 1
and 2 diabetes was carried out by the Welcome Trust Case
Control Consortium [51]. Since GWAS studies rely on
control populations it is very important that for different
population SNP haplotypes will be investigated prior to
undertaking such studies.
The integration of data sets from genomics and tran-
scriptomics platforms will have an impact in the future for
disease stratification and testing for individual genomic
variations leading to the final goal of HGP: the prevention
of disease and the introduction of therapies based on
individual genomics information [52].
Ethical issues
Genetic testing has some aspects that differentiates it from
other medical tests, requiring the use of an entirely different
ethical framework [53–55]. This type of testing has
implications for the individual, family and the society
[56]. For the individual, the decision to test should take into
account the benefits versus the risks, such as the psycho-
logical effects, and stigmatization. For the members of the
family, the result of the testing will have the potential of
stigmatization, parental guilt and anxiety in individual
members of the family knowing they may also run the risk
of a certain disease. Societies need to be able to debate and
reflect on basic ethical questions such as the right to access
health care, non-marginalization and discrimination [57]. In
some diseases such as X-linked monogenic diseases, the
determination of the gender of the fetus may have
predictive value. However, in some societies, sex determi-
nation may also be used as a method of selecting babies
with a desired gender. This is, of course, against basic
ethical values such as human dignity and human rights.
There are different phases during a genetic test that need to
be governed. An ideal flow of the procedures would begin with
pre-testing counseling and end with post-testing counseling.
Furthermore, basic ethical guidelines should be followed: a
written informed consent must be obtained from the parents or
legal guardians of pediatric patients; the privacy of the data and
confidentiality during testing must be secured and the results
must not be released to third parties such as school officials or
insurance agencies without authorization [58].
There are presently no treatments for most genetic
disorders, so testing does not alter the course of the disease
or its outcome. Thus, the question of testing will become an
ethical dilemma that needs careful reflection on the part of
medical practitioner and the family of the patient. In
particular, predictive testing in children for adult onset
disorders calls for special attention to the psychological
risks such as anxiety attached to testing [59].
Considering the ethical, social and psychological burden of
genetic testing, counseling becomes an integral part of
services both before and after testing as previously mentioned.
Quality assurance and governance
The quality of genetic testing must be assured in order to
minimize risk due to erroneous results [60]. This is possible
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through licensing, accreditation and certification as the
methods of oversight for laboratories that offer genetic
testing. To gain a license, a laboratory has to have
authorization from a relevant government agency. Through
accreditation, the competence of the laboratory is bench-
marked against an external standard. Certification is a
method to indicate the assessment of the quality manage-
ment of the laboratory and both procedures are dependent
on external audits [61].
The analytical validity of the tests from a laboratory
performing genetic testing is usually benchmarked through
an external quality assurance scheme (EQA) or proficiency
testing. Besides laboratory procedures used for the tests,
other procedures such as the interpretation of results and
issuing of the patients’ reports are very important indicators
of quality assurance for genetic testing laboratories.
Europe wide efforts are being implemented to increase the
quality of genetic testing. One example is the EC Project
EuroGentest, which is an NoE (network of excellence) project
supported through the Framework Programs (FP6) with the
mission to harmonize the genetic testing. The major outputs of
the project are the organization of external quality assurance
schemes, advice on accreditation and certification of genetic
testing services, and the development of guidelines for genetic
testing (www.eurogentest.org). Another European effort to
promote quality in genetic testing is European Molecular
Genetics Quality Assurance Network (EMQN) (www.emqn.
org) which works closely with EuroGentest and the CF
Network to provide external quality assessment schemes to
many labs in Europe and worldwide.
Conclusion and perspectives
Genomics offers powerful tools for health care systems
where early predictive value of genetic markers can be
exploited for the prevention and personalized therapy of
disease. These tools are being used to develop genetic tests
in monogenic diseases and it is expected that multifactorial
disease diagnosis and management will also benefit from
genomics approaches. To be able to incorporate the use of
predictive disease markers in the clinical applications, we
need to wait for the reduction of cost, in order to increase
their applicability in health care systems. To be able to
detect the risk of disease at a very early stage, even in
prenatal stages of life, more non-invasive methods of
sampling such as fetal cells in the maternal circulation
and cell free fetal nucleic acid needs to be developed and
their sensitivity and robustness should be tested. More
medical professionals need to be informed about genomics
(and other *omics technologies) to be able to use them for
the benefit of their patients, that needs a new approach in
medical education in the new era of medicine. Furthermore,
awareness in the societies is necessary for proper
application of new technologies and demand for genetic
testing as a part of health care delivery systems.
Predictive testing is already beginning to become a large
market item [62]. Especially in terms of consumer
benefits; genetic testing becomes an issue for different
levels of regulations [63].
Since the ultimate benefit of determining the risk at an
early stage of a disease development advantages by
personalized management and treatment of disease, in
different societies should be covered in terms of their
access to genomic technologies. This is a bioethical concern
when health is considered as a common good for all human
beings and access to adequate health care is a basic ethical
imperative of human dignity. As a result, international
collaborations and open access to information is crucial to
remove the disparities in genomics medicine for many
countries: when used properly, genomics holds hope for
prediction, prevention and treatment of disease based on
individual patients profiles.
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